tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

SSY Group Secures Key Drug Approvals in China

Story Highlights
SSY Group Secures Key Drug Approvals in China

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from SSY Group ( (HK:2005) ) is now available.

SSY Group Limited has announced that it received approvals from the National Medical Products Administration of China for the production and registration of three new drugs: Urapidil Sustained-release Capsules, Nicardipine Hydrochloride and Sodium Chloride Injection, and Drotaverine Hydrochloride Injection. These approvals mark significant milestones as they are the first of such approvals for these types of drugs in China, potentially enhancing SSY Group’s market position and expanding its product offerings in the pharmaceutical industry.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited is a company involved in the pharmaceutical industry, focusing on the development and production of chemical drugs. Their primary products include medications for hypertension and smooth muscle spasms, with a market focus on providing treatments for these conditions in China.

YTD Price Performance: -17.80%

Average Trading Volume: 13,270,514

Technical Sentiment Signal: Sell

Current Market Cap: HK$8.38B

Learn more about 2005 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1